Successful medical therapy for endocarditis due to Candida parapsilosis. A clinical and epidemiologic study

• Published in: Chest Vol. 73; no. 4; p. 546
• Main Authors: Mayrer, A R, Brown, A, Weintraub, R A, Ragni, M, Postic, B
• Format: Journal Article
• Language: English
• Published: United States 01.04.1978
• Subjects: Adult; Amphotericin B - therapeutic use; Candida - isolation & purification; Candidiasis - drug therapy; Endocarditis - drug therapy; Endocarditis - etiology; Flucytosine - therapeutic use; Humans; Male
• ISSN: 0012-3692
• DOI: 10.1378/chest.73.4.546

A heroin addict with asymmetric septal hypertrophy and persistent fungemia with Candida parapsilosis was treated with amphotericin B and flucytosine (5-fluorocytosine). The diagnosis of endocarditis was based on the subsequent development of a murmur of mitral regurgitation and echocardiographic evidence of prolapse of the posterior leaflet of the mitral valve. Cure was effected with antifungal therapy alone. Thus, when the diagnosis of fungal endocarditis is made early in its course, open-heart surgery may not be needed. To investigate the relative frequency of isolation of C parapsilosis from particular sites, a mycologic survey was conducted in our hospital. Among the isolates of yeasts, C parapsilosis represented 8.0, 17.1, and 26.7 percent of those from all cultured sites, from contaminated intravenous catheters, and from cultures of blood, respectively. Since this trend to cluster in cases of fungemia was not seen with other yeasts, C parapsilosis appears to be more invasive than other species of Candida.